About Prothena Corporation PLC (NASDAQ:PRTA)
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. The Company's pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:PRTA
- CUSIP: N/A
- Web: www.prothena.com
- Market Cap: $2.22 billion
- Outstanding Shares: 38,275,000
- 50 Day Moving Avg: $62.65
- 200 Day Moving Avg: $57.71
- 52 Week Range: $40.58 - $70.00
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.02
- P/E Growth: 0.78
- Annual Revenue: $27.53 million
- Price / Sales: 80.57
- Book Value: $12.76 per share
- Price / Book: 4.54
- EBITDA: ($135,600,000.00)
- Net Margins: -527.56%
- Return on Equity: -33.20%
- Return on Assets: -27.66%
- Current Ratio: 12.93%
- Quick Ratio: 12.93%
- Average Volume: 227,002 shs.
- Beta: 2.59
- Short Ratio: 22.03
Frequently Asked Questions for Prothena Corporation PLC (NASDAQ:PRTA)
What is Prothena Corporation PLC's stock symbol?
Prothena Corporation PLC trades on the NASDAQ under the ticker symbol "PRTA."
How were Prothena Corporation PLC's earnings last quarter?
Prothena Corporation PLC (NASDAQ:PRTA) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.89) by $0.43. The company earned $26.81 million during the quarter, compared to analysts' expectations of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business's quarterly revenue was up 7951.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.18) earnings per share. View Prothena Corporation PLC's Earnings History.
When will Prothena Corporation PLC make its next earnings announcement?
Where is Prothena Corporation PLC's stock going? Where will Prothena Corporation PLC's stock price be in 2017?
12 brokerages have issued 12-month price objectives for Prothena Corporation PLC's shares. Their forecasts range from $69.00 to $100.00. On average, they expect Prothena Corporation PLC's stock price to reach $79.73 in the next twelve months. View Analyst Ratings for Prothena Corporation PLC.
What are analysts saying about Prothena Corporation PLC stock?
Here are some recent quotes from research analysts about Prothena Corporation PLC stock:
- 1. Cantor Fitzgerald analysts commented, "Gotta be in it to win it. The logic behind impeding cell trafficking as a means treating T cell-mediated autoimmune disorders has been established with Tysabri in relapsing forms of MS, so the merits of pursuing non-CNS indications makes abundant sense to us." (9/28/2017)
- 2. According to Zacks Investment Research, "The narrower-than-expected loss in the second quarter was encouraging. Prothena’s efforts on developing its pipeline are encouraging. The company's license agreement with Roche for the development and commercialization of selected antibodies targeting alpha-synuclein is a big positive. The collaboration not only boosts Prothena’s pipeline development but also provides it with funds in the form of research reimbursement and milestone payments. Prothena recently earned a $30 million of milestone payment from Roche. The company’s shares have outperformed the industry in the past one year. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001. However, Prothena is highly dependent on its collaboration partners for the development of its candidates. The company itself does not have enough resources to independently conduct studies on its candidates." (8/11/2017)
- 3. Instinet analysts commented, "We are initiating on Prothena Corporation (PRTA) with a Buy rating and an $87 target price. We recommend owning PRTA shares ahead of Phase 2b PRONTO trial readout expected in early 2018 for lead asset NEOD001 in AL amyloidosis (a >$1.5bn peak sales opportunity). We view the pullback from 2016 highs and recent lows as an opportunity to accumulate the shares ahead of PRONTO data. Positive results from PRONTO based on change in NT-proBNP, a biomarker that NEOD001 substantially moved, yielding 53% responder rate in an early Phase 1/2b, are likely to support a conditional approval in the EU by 2019. In addition, we expect biomarker data from the PRX003 Phase 1b study to define mechanistically the breadth opportunity for MCAM/Th17-cell targeting in autoimmune disease, a potential multibillion dollar opportunity that, in our view, will raise the floor on PRTA's valuation. PRX002 could become a strong driver of PRTA's valuation in out years; however, given few near-term catalysts, it is unlikely to be a driver for PRTA shares in the next 12 months." (3/1/2017)
Who are some of Prothena Corporation PLC's key competitors?
Some companies that are related to Prothena Corporation PLC include Clovis Oncology (CLVS), Sarepta Therapeutics (SRPT), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Array BioPharma (ARRY), Insmed (INSM), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS) and Acceleron Pharma (XLRN).
Who are Prothena Corporation PLC's key executives?
Prothena Corporation PLC's management team includes the folowing people:
- Lars G. Ekman M.D., Ph.D., Independent Chairman of the Board
- Gene G. Kinney Ph.D., President, Chief Executive Officer, Director
- Tran B. Nguyen, Chief Financial Officer
- Karin L. Walker CPA, Chief Accounting Officer, Controller
- Wagner Zago, Chief Scientific Officer
- Arthur W. Homan, Chief Legal Officer
- Carol D. Karp, Chief Regulatory Officer
- Martin Koller M.D., Chief Medical Officer
- Tara Nickerson Ph.D., Chief Business Officer
- K. Anders O. Harfstrand M.D., Ph.D., Director
Who owns Prothena Corporation PLC stock?
Prothena Corporation PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include Nationwide Fund Advisors (0.05%) and Strs Ohio (0.01%). Company insiders that own Prothena Corporation PLC stock include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker, Lars Ekman, Martin Koller, Tara Nickerson and Tran Nguyen. View Institutional Ownership Trends for Prothena Corporation PLC.
Who sold Prothena Corporation PLC stock? Who is selling Prothena Corporation PLC stock?
Prothena Corporation PLC's stock was sold by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. Company insiders that have sold Prothena Corporation PLC stock in the last year include Arthur W Homan, Christopher S Henney, Dennis J Selkoe, Gene G Kinney, Karin L Walker and Tara Nickerson. View Insider Buying and Selling for Prothena Corporation PLC.
Who bought Prothena Corporation PLC stock? Who is buying Prothena Corporation PLC stock?
How do I buy Prothena Corporation PLC stock?
Shares of Prothena Corporation PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prothena Corporation PLC's stock price today?
MarketBeat Community Rating for Prothena Corporation PLC (NASDAQ PRTA)MarketBeat's community ratings are surveys of what our community members think about Prothena Corporation PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Prothena Corporation PLC stock can currently be purchased for approximately $57.95.
Consensus Ratings for Prothena Corporation PLC (NASDAQ:PRTA) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||12 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$79.73 (37.58% upside)|Consensus Price Target History for Prothena Corporation PLC (NASDAQ:PRTA)
Analysts' Ratings History for Prothena Corporation PLC (NASDAQ:PRTA)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/23/2017||Deutsche Bank AG||Set Price Target||Buy||$73.00||N/A|
|10/2/2017||Jefferies Group LLC||Reiterated Rating||Buy||$100.00||Low|
|10/2/2017||SunTrust Banks, Inc.||Reiterated Rating||Buy||$75.00||Low|
|9/29/2017||Royal Bank Of Canada||Reiterated Rating||Buy||High|
|9/29/2017||BTIG Research||Lower Price Target||Buy -> Buy||$80.00 -> $77.00||High|
|9/28/2017||Cantor Fitzgerald||Reiterated Rating||Buy||$79.00||Medium|
|8/16/2017||Evercore ISI||Initiated Coverage||Outperform -> Outperform||$83.00||High|
|7/6/2017||Oppenheimer Holdings, Inc.||Reiterated Rating||Outperform||$70.00||Low|
|5/16/2017||Piper Jaffray Companies||Reiterated Rating||Buy||Medium|
|3/1/2017||Instinet||Initiated Coverage||Buy -> Buy||$87.00||N/A|
|9/27/2016||Credit Suisse Group||Reiterated Rating||Buy||$65.00||N/A|
|8/4/2016||Barclays PLC||Boost Price Target||Overweight||$60.00 -> $70.00||N/A|
Earnings History for Prothena Corporation PLC (NASDAQ:PRTA)Earnings History by Quarter for Prothena Corporation PLC (NASDAQ PRTA)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/8/2017||6/30/2017||($0.89)||($0.46)||$16.08 million||$26.81 million||View||N/A|
|5/9/2017||3/31/2017||($1.32)||($0.99)||$0.26 million||$0.26 million||View||N/A|
|2/14/2017||Q416||($1.12)||($1.41)||$5.35 million||$0.20 million||View||Listen|
|11/1/2016||Q3||($1.22)||($1.26)||$0.49 million||$0.29 million||View||N/A|
|8/2/2016||Q2||($0.91)||($1.18)||$0.39 million||$0.33 million||View||N/A|
|5/3/2016||Q116||($0.77)||($0.81)||$0.27 million||$0.27 million||View||N/A|
|2/18/2016||Q215||($0.81)||($0.76)||$0.39 million||$0.31 million||View||Listen|
|11/2/2015||($0.66)||($0.73)||$0.28 million||$0.43 million||View||N/A|
|8/4/2015||Q2||($0.56)||($0.59)||$0.60 million||$0.28 million||View||N/A|
|5/5/2015||($0.59)||($0.55)||$1.95 million||$0.59 million||View||N/A|
|3/5/2015||Q414||($0.66)||($0.48)||$1.20 million||$2.00 million||View||N/A|
|11/3/2014||Q314||($0.60)||($0.48)||$1.13 million||$1.50 million||View||N/A|
|8/4/2014||Q214||$0.06||$15.17 million||$15.12 million||View||N/A|
|5/5/2014||$0.81||$0.78||$30.17 million||$32.23 million||View||N/A|
|3/28/2013||Q412||($0.82)||$0.13 million||$0.58 million||View||N/A|
Earnings Estimates for Prothena Corporation PLC (NASDAQ:PRTA)
2017 EPS Consensus Estimate: ($5.08)
2018 EPS Consensus Estimate: ($4.58)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Prothena Corporation PLC (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Prothena Corporation PLC (NASDAQ:PRTA)
Insider Ownership Percentage: 3.10%Insider Trades by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||Dennis J Selkoe||Director||Sell||3,500||$64.17||$224,595.00|| |
|9/28/2017||Christopher S Henney||Director||Sell||900||$70.00||$63,000.00|| |
|9/28/2017||Gene G Kinney||Insider||Sell||2,800||$70.00||$196,000.00|| |
|9/27/2017||Tara Nickerson||Insider||Sell||4,724||$69.05||$326,192.20|| |
|9/25/2017||Tara Nickerson||Insider||Sell||17,500||$63.60||$1,113,000.00|| |
|7/17/2017||Karin L Walker||Insider||Sell||5,000||$64.89||$324,450.00|| |
|7/7/2017||Dennis J Selkoe||Director||Sell||3,500||$58.11||$203,385.00|| |
|4/17/2017||Karin L Walker||Insider||Sell||5,000||$52.25||$261,250.00|| |
|4/3/2017||Dennis J Selkoe||Director||Sell||3,500||$55.86||$195,510.00|| |
|3/9/2017||Tran Nguyen||CFO||Buy||1,000||$51.32||$51,320.00|| |
|1/4/2017||Arthur W Homan||Insider||Sell||3,125||$52.25||$163,281.25|| |
|11/28/2016||Dennis J Selkoe||Director||Sell||5,000||$62.42||$312,100.00|| |
|11/9/2016||Gene G Kinney||Insider||Sell||8,548||$55.32||$472,875.36|| |
|10/21/2016||Gene G Kinney||Insider||Sell||20,619||$55.10||$1,136,106.90|| |
|10/13/2016||Karin L Walker||Insider||Sell||5,000||$54.23||$271,150.00|| |
|9/19/2016||Karin L Walker||Insider||Sell||12,000||$61.10||$733,200.00|| |
|9/1/2016||Arthur W Homan||Insider||Sell||3,125||$52.16||$163,000.00|| |
|7/20/2016||Arthur W Homan||Insider||Sell||9,375||$52.14||$488,812.50|| |
|5/24/2016||Dennis J Selkoe||Director||Sell||5,000||$45.00||$225,000.00|| |
|4/13/2016||Karin L Walker||Insider||Sell||4,000||$45.11||$180,440.00|| |
|4/4/2016||Dennis J Selkoe||Director||Sell||5,000||$45.00||$225,000.00|| |
|1/13/2016||Karin L. Walker||insider||Sell||4,000||$50.96||$203,840.00|| |
|12/9/2015||Tara Nickerson||insider||Sell||10,000||$66.17||$661,700.00|| |
|12/9/2015||Tran Nguyen||CFO||Sell||30,000||$66.17||$1,985,100.00|| |
|12/1/2015||Dennis J. Selkoe||Director||Sell||3,125||$68.74||$214,812.50|| |
|11/27/2015||Christopher S. Henney||Director||Sell||5,000||$75.00||$375,000.00|| |
|11/25/2015||Lars Ekman||Director||Sell||30,000||$73.35||$2,200,500.00|| |
|11/13/2015||Martin Koller||insider||Sell||30,000||$65.03||$1,950,900.00|| |
|11/2/2015||Arthur W. Homan||insider||Sell||3,125||$52.14||$162,937.50|| |
|10/29/2015||Christopher S. Henney||Director||Sell||5,000||$55.00||$275,000.00|| |
|9/9/2015||Tara Nickerson||insider||Sell||10,000||$56.06||$560,600.00|| |
|9/2/2015||Martin Koller||insider||Sell||30,000||$55.56||$1,666,800.00|| |
|9/1/2015||Dennis J. Selkoe||Director||Sell||3,125||$55.45||$173,281.25|| |
|8/20/2015||Dale B. Schenk||CEO||Sell||30,000||$56.65||$1,699,500.00|| |
|8/12/2015||Karin L Walker||Insider||Sell||7,000||$62.06||$434,420.00|| |
|6/9/2015||Tara Nickerson||Insider||Sell||12,000||$44.41||$532,920.00|| |
|3/20/2015||Tara Nickerson||Insider||Sell||13,000||$39.99||$519,870.00|| |
|3/9/2015||Dennis J Selkoe||Director||Sell||3,125||$25.56||$79,875.00|| |
|8/12/2014||Karin L Walker||Insider||Sell||2,500||$20.74||$51,850.00|| |
|8/7/2014||Arthur W Homan||Insider||Buy||2,000||$19.12||$38,240.00|| |
|6/6/2014||Karin L Walker||Insider||Sell||8,000||$21.58||$172,640.00|| |
|5/12/2014||Dale Schenk||CEO||Buy||8,000||$20.79||$166,320.00|| |
|5/12/2014||Tara Nickerson||Insider||Buy||1,656||$21.00||$34,776.00|| |
|5/9/2014||Gene Kinney||Insider||Buy||2,500||$19.54||$48,850.00|| |
|5/9/2014||Tran Nguyen||CFO||Buy||2,200||$19.61||$43,142.00|| |
|2/3/2014||Co Plc Perrigo||major shareholder||Sell||3,182,253||$24.96||$79,429,034.88|| |
Headline Trends for Prothena Corporation PLC (NASDAQ:PRTA)
Latest Headlines for Prothena Corporation PLC (NASDAQ:PRTA)
Loading headlines, please wait.
Prothena Corporation PLC (PRTA) Chart for Monday, October, 23, 2017